Qian Qin

A Phase II, open-label, single-arm study of nEoadjuvant zanzalintinib (XL092) Plus nivoLumab in patients with locally advanced and/or surgically challenging clear cell Renal Cell Carcinoma with or without non-measurable metastasis (EXPLORE-RCC)